Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06401044 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

StatusActive, Not Recruiting
PhasePhase 1/2
SponsorAmgen
Started2024-05-30
View on ClinicalTrials.gov ↗
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.

Amendment history 7 changes detected by DataLookout

2026-08-11
Enrollment closed, study ongoing
2026-08-11
Primary completion moved earlier: 2027-02-22 → 2027-01-06
2026-08-11
Completion pushed: 2027-08-13 → 2027-12-24
2026-07-11
Trial sites expanded: 40 → 44 locations
2026-06-13
Trial sites expanded: 34 → 38 locations
2026-05-16
Trial sites expanded: 30 → 34 locations
2026-03-31
Trial sites expanded: 23 → 28 locations
Trial Details
NCT Number NCT06401044
Lead Sponsor Amgen
Conditions Thyroid Eye Disease
Enrollment 94 participants
Start Date 2024-05-30
Primary Completion 2027-01-06 (estimated)
Study Completion 2027-12-24 (estimated)
Updated on ClinicalTrials.gov 2026-08-10